Home Authors Posts by Filip Teodor

Filip Teodor



 Restore Cerebral Blood Flow After Stroke

Researchers have created a new device that helps restore cerebral blood flow after a stroke. Solitaire flow restoration, as it  is called has proven to be more efficient compared with standard mechanical device used before. Solitaire device flow restoration, which was recently approved by the FDA, is a new class of medical devices that help restore cerebral blood flow. The new device was evaluated and compared with the standard device (MERCI Retriever) in a randomized trial.

The study included 58 patients who were treated with Solitaire flow restoration device and 55 patients who were treated with the Merci retriever system. Conditions necessary for patients to be included in the study were that they have moderate to severe neurological deficits that be treated by thrombectomy in up to 8 hours after stroke. The average patient age was 67 years, and more than half of the patients were men (68%). It was found that Solitaire flow restoration device was successful in 61% of patients, unlike the Merci retriever system that has been successful in only 24% of patients. In addition, it was found that the new device was superior to standard device in terms of mortality rates. Among those treated with Solitaire flow restoration, mortality was 17.2%, while among those treated with the Merci Retriever, the mortality rate was 38.2%.

Sloiraire Flow Restoration

Solitaire Flow Restoration Device

Solitaire flow restoration device is intended to restore blood flow in cerebral vessels in patients with acute cerebral ischemia. Stroke occurs due to cerebral ischemia in a certain territory. The causes of a stroke  can be thrombosis  or hemorrhage. Stroke is considered a medical emergency because it can lead to irreversible brain damage and even death. Depending on the location of the clogged artery,  there may occur symptoms like blurred vision, dizartry, hemiplegia, altered movement coordination and others. There are several risk factors involved in the development of stroke, such as hypertension, diabetes, hypercholesterolemia, smoking, etc.. It is important to note that these factors can be influenced by lifestyle changes. Studies have shown that by controlling high blood pressure, stroke risk drops significantly.

Solitaire Flow Restoration

Solitaire Flow Restoration

As far as the treatment is concerned, there may be a medical or surgical approach. If the stroke was caused by a blood clot, it can be dissolved by thrombolysis (clot buster): rPA, alteplase. Surgical treatment consists in removing thrombus causing stroke (endarterectomy, thrombectomy). Patients who do not have an indication for thrombolytic therapy or patients in whom this treatment is ineffective,  mechanical embolectomy devices can be used. Another option could be angioplasty.


Recent Study Links T. Gondii Parasite to Suicidal Attempts

Scientists have discovered that a very common and known to be harmless parasite can cause small changes in the brain that might actually lead to suicide attempts.

Toxoplasma gondii, or T. gondii can be found in almost a third of the world’s population. Although in most people it lies dormant, it  can also cause toxoplasmosis. People can easily catch it by consuming undercooked meat, especially pork or lamb and by drinking contaminated water. The parasite reproduces in the cells of its primary hosts, all members of the feline family.

Toxoplasmosis can have serious effects on a fetus whose mother develops the disease during pregnancy or on an immunocompromised person. In time, brain inflammation may appear, which will release metabolites into the organism, damaging the brain cells.

Previous studies had found  T.gondii  responsible for behavioral changes and even suicide attempts.  Researchers revealed that  suicide victims and depressed patients presented small areas in the cerebrum with evidence of inflammation. A more recent study, led by professor Lena Brundin, has shown that people who are positive for the parasite are seven times more likely to attempt suicide.

Brundin and her team are the first ones to measure scores on a suicide assessment scale from people who have the parasite. They found that those who tested positive for Toxoplasma gondii were placed on a considerably higher spot on the scale, being more susceptible to severe diseases and future suicide attempts. On the other hand, professor Brundin highlighted the fact that for different reasons some individuals are more at risk of developing symptoms than others.

“It is estimated 90 percent of people who attempt suicide have a diagnosed psychiatric disorder. If we could identify those people infected with this parasite, it could help us predict who is at a higher risk”, said  Brundin.

Toxoplasma Gondii

Toxoplasma Gondii

With over a decade of work behind, professor Brundin has discovered that the most effective treatment for depression is a class of antidepressants called selective serotonin re-uptake inhibitors or SSRIs. These selective inhibitors increase the level of serotonin, a neurotransmitter contributor to feelings of happiness and well-being. Moreover, her research also indicated that a low serotonin level in the cerebrum might be a symptom of depression and not the cause of it.

Depression is more likely to be caused by inflammation in the brain, from an infection or parasite rather than a serotonin reduction. According to professor Brundin, when parts of the brain are inflamed, its chemistry changes, which can easily cause depression and even suicide thoughts.

Lena Brundin also stated that biological changes are good constructive signs in people with suicidal thoughts because it helps develop new treatments in order to prevent this disease and gives patients the help they need to overcome depression.


Study Shows Stem Cells Are Able to Prevent Post-traumatic Arthritis

A new study led by scientists from the Duke University reveals a new stem cell therapy that is capable of preventing the onset of osteoarthritis after a joint injury. The risk of osteoarthritis increases after joint injury. The form of osteoarthritis that appears after injuries is called post-traumatic arthritis (PTA). Currently there are no known therapies that can slow down the progression of arthritis once joint injury occurs.

Scientists from the Duke University Health System have discovered a new therapeutic approach towards post-traumatic arthritis by using a type of stem cell called MSC (mesenchymal stem cell). In their study, researchers used laboratory mice that suffered various fractures that would normally lead to the onset of osteoarthritis. The results of the study might lead to the development of a new therapy that will be used after the joint injury but before any signs of osteoarthritis appear.

Researchers assumed that these mesenchymal stem cells would have a positive effect of preventing the onset of post-traumatic osteoarthritis due to their already other beneficial properties in the other regions of the organism. “The stem cells were able to prevent post-traumatic arthritis”, said Farshid Guilak, who is also the director of orthopedic research at Duke University. The findings of the study were published on the 10th of August in the journal Cell Transplantation.



 Another assumption made by the researchers was that by using a special type of laboratory mice that have increased healing capabilities, the effect of the stem cells would be greater. However, this assumption was later proven to be wrong.

Brian Diekman, the lead author of the study, says that the research team wanted to investigate whether the stem cells take from this special breed of laboratory mice are superior to the ones taken from ordinary mice. The study has shown that the effects of the two types of stem cells are very much similar. ” We were surprised “ and excited “ to learn that regular stem cells work just as well”, added Diekman.

Guilak, who is also a professor of orthopedic surgery at the Duke University said that there are certain types of people who also have these increased healing capabilities. These patients normally heal better and faster after fractures and some of the don’t even suffer from post-traumatic osteoarthritis. He added that this increased healing ability could be caused by some other beneficial factor and not by stem cells.

In order to prevent the onset of  post-traumatic osteoarthritis, each mouse received either 10,000 typical or 10,000 special stem cells. There was also a control group that received a saline solution. Diekman reported that the research team studied the  markers of inflammation and discovered that the stem cells affected the inflammatory environment. He said that the stem cells altered the levels of cytokines (protein molecules that have an important role in intercellular communication), thus altering the bone healing response.

The authors of the study mentioned that they used mesenchymal stem cells, instead of other stem cells, because these are stem cells that do not later become part of the blood. One challenge that they encountered is the possibility of isolating these specific stem cells, which are a rare cell type found in the bone marrow.  “We found that by placing the stem cells into low-oxygen conditions, they would grow more rapidly in culture so that we could deliver enough of them to make a difference therapeutically”, said Diekman.



Researchers at the University of Leeds have found that ranolazine, a drug used as anti-anginal and anti-ischemic, is useful in the treatment of carbon monoxid poisoning. Carbon monoxide is a toxic gas resulting from incomplete combustion (cooking equipment, house fires, etc.) and can be fatal if it is not treated in time. Carbon monoxide gas is odorless, tasteless and colorless, so it is difficult to detect by humans. In carbon monoxide poisoning, symptoms vary depending on the concentration and amount of gas that form carboxyhemoglobin.

The first symptoms are represented by headaches and confusion, then  tachycardia, dizziness, convulsions, respiratory arrest and eventually coma and death occurs. The most affected organs affected in carbon monoxide poisoning are the brain and heart tissue, organs which depend most on oxygen . Treatment of carbon monoxide poisoning consists mainly of administration of hyperbaric oxygen, along with correcting other imbalances that occur (cardiac arrhythmias, acidosis, pulmonary edema, convulsions).

Researchers found that exposure to carbon monoxide alters ion transport through cell membranes, thereby calcium ions accumulate inside the cell and cause arrhythmias. University of Leeds’ Professor Chris Peers, who led the research, points out that this is the first study to clarify the mechanism by which carbon monoxide lead to arrhythmias. The researchers wanted to test the protective effect of ranolazine on the heart and found that this drug reduces the risk of arrhythmias in laboratory animals exposed to carbon monoxide. Furthermore, researchers believe that this drug may be useful for those chronically exposed to carbon monoxide, such as firefighters.

Ranolazine Tablets

University of Leeds’ Professor Chris Peers, who led the research, pointed out that when dealing with a patient with carbon monoxide poisoning the first thing to do is to stop the damage caused by the gas in the body. He added that studies have shown that ranolazine protects the heart and prevent cardiac arrhythmias caused by gas. Ranolazine is a drug approved in 2006 for treatment of angina pectoris. This drug presents anti-anginal effects and has the advantage of not affecting heart rate or blood pressure .

Ranolazine is indicated for patients with angina who remain symptomatic after maximal doses of antianginal drugs. Because it is metabolized by CYP3A, ranolazine should not be taken simultaneously with certain drugs, such as calcium channel blockers (diltiazem, verapamil) or ketoconazole. Also it should be noted that ranolazine increases the QTc interval. Therefore, this drug is not recommended in certain patients (such as those with preexisting QT prolongation or those taking CYP3A inhibitors, and so on).


Galaxy Note 2

Samsung was and probably will be one of the best gadget manufacturers, able to fully squeeze the juice from an Android operating system. The Koreans at Samsung know sure how to build a strong reputation around their device, even if it has not even seen the market shelves yet, attracting more and more customers and incorporating increasingly more market share. This is also the case of Galaxy Note 2, device which has kept us curious for months before the official release and even with a bunch rumors available all around the web, there are still known facts about it. What we currently know is that the new Galaxy Note 2 will be released in Berlin on August 29, and it will pack an Exynos 4412 processor (i hope you all know what this baby can do) along with a Super AMOLED display with a diameter of 5.5 inch. But here is where it all halts. This is pretty much all we knew  ‘for sure’ until today regarding the new Galaxy Note 2.

Galaxy note

Galaxy note

Today we may reconsider these facts as the Korea IT Times claims to have received from an anonymous tipster that the new Galaxy Note 2 will pack not a regular AMOLED display but a flexible 5.5 inch display. Yes you heard right, we are talking about flexible display technology here, technology that Samsung at least unofficially has been trying to implement for a while now. If this is the case, the Galaxy Note 2 will be the first Samsung device that will be exit the production equipped with such breathtaking technology.

The only down side will probably be that probably the new Galaxy Note 2 flexible display won’t be so flexible and you won’t get to play with it as much as you imagined. As the title says it will be semi-flexible coming out of the box with some sort of bend. This approach, along with the use of the Unbreakable Plane and of course a plastic substrate, will be the strategy behind a thickness reduction of 0,5 millimeters. On the other hand, Samsung seems not to plan a Galaxy Note 2 thinner than its predecessor as there are plans to equip the next generation of Galaxy Tab with a larger battery. We all know that the Galaxy Note features a 2,500 mAh battery that is not put to shame, and this makes us also hope for an excellent battery life for the Galaxy Note 2.


iPhone 5 Release Date September 12, iPad Mini Still Uncertain

The new iPhone 5 could reach our physician hands faster than we expected, as multiple rumors emerged yesterday indicating the imminence of an Apple event on September 12. If the purpose of this event is unknown, in the best tradition Apple iPhone terminal 5 is a product that has the best chance to star in the foreground.  Apple’s first handset that will abandon the 3.5 inch diagonal, the iPhone 5 was the subject of many rumors and more or less truthful affirmations leaked in the press. According to 9to5Mac, the next generation iPhone i now passing the EVT (Engineering Verification Test) internal testing, with two variants – iPhone 5.1 and iPhone 5.2 – selected as candidates for the finished product. Both iPhone versions are equipped with 3.95 inch screen, displays capable of  a non-standard resolution of 1136×640 pixels.

 Iphone and Ipad

Picture Of Iphone and Ipad

If rumors are true the elongated format of the display requires changes of software to adapt applications and the operating system interface, which will meanwhile reach the IOS 6 version.With the new widescreen, iPhone 5 could accommodate an expanded set of applications on home screen, represented using five rows of icons. Additionally, we have more room for applications interface elements, accommodated without restricting the space for displaying content. Given the very close aspect ratio to the 16:9 aspect ratio, wide-screen movies will finally be viewed without black bars in maximized mode.

If iPhone 5 is released on September 12, it will be available from September 21. As for the certainty of the rumors regarding the iPad Mini, the iPad version reduced in size and price, of the current iPad tablet we can not say the same thing. While some sources say it will be released in September, with  the new iPhone 5,   others claim that the new tablet it is ready yet and would benefit from a separate event sometime in October or November.  With the new product, the IOS operating system will make the jump to the 6.0version. As Beta 3 version has only two weeks, it seems that the company’s software developers will have more work to move through Release Candidate in very short time interval.


Rheumatic Chorea

Rheumatic chorea was first described by Thomas Sydenham in 1684, referring to it as a minor choreic syndrome. In 1780, Stoll was the first who observed a relationship between Sydenham chorea and rheumatic fever, but Cheadle is the one that described the main symptoms of rheumatic fever syndrome: carditis, polyarthritis, chorea, subcutaneous nodules and erythema marginatum.  The link between streptococcal infection and rheumatic chorea was establish in the twentieth century.

Recent studies show that Sydenham chorea may be associated with certain neuropsychiatric disorders such as obsessive compulsive disorder, attention deficit-hyperactivity disorder (ADHD),anxiety and depression.

Sydenham chorea is the most common cause of acute acquired chorea in young people and is associated with group A beta hemolytic streptococcal infection, the causative agent of rheumatic fever. The incidence of rheumatic fever is 0,5-2 cases per 100,000 inhabitants, but Sydenham chorea represents the main manifestation of acute rheumatic fever in approximately 20% of cases. Rheumatic chorea is more common in females, female/male ratio being 2 to 1.

Sydenham Chorea Causes

Sydenham chorea is a result of an immunological cross-reaction, in which immunoglobin G antibodies produced as a response to antigens in the membrane of group A streptococci, cross-react to antigens (tubulin and lysoganglioside) in the neuronal cytoplasm of the caudate and subthalamic nuclei, due to an immunological similarity between streptococcal and neuronal antigens. In the support of this mechanism were also highlighted high levels of antineuronal antibodies in the cerebrospinal fluid and in the serum of patients with Sydenham chorea.

Sydenham Chorea Symptoms

The disease occurs predominantly in children aged between 5 and 15 years, with a slight predominance in females. Onset may be acute, symptoms develop within a few days or subacute with a progressive appearance of symptoms, over several weeks. At first patients can be very nervous, anxious and have difficulties in writing, drawing and other manual activities, unsteady gait and grimacing.

Choreic movements amplify as the disease evolve, are short, disordered, quick, sudden and polymorphic, localized in the hand and feet fingers and in evolution will interfere with breath and speech. Children begin to drop objects from hand, writing deforms and becomes illegible.

Sudden alterations in rhythm and amplitude of breathing may occur and interfere with the normal rhythm of speech. Speech becomes explosive, uncomprehensive, not only due to respiratory dysrhythmia, but also to involuntary muscle contractions of the tongue, lips, neck and facial muscles. A variable intensity of muscle weakness may be present, leading to inability to sustain a contraction. In clinical forms with predominance of hypotonia (mild chorea) hyperkinesia is attenuated. Singns of muscle weakness and hypotonia are represented by choreic hand (the arms are extended, the wrist will flex and the metacarpophalangeal joints overextend) and by the pronator sign (hyperpronation of the hands, causing the palms to face outward when the arms are held over the head). In most cases choric movements are limited to one side of the body (hemichorea).

It was also describes a form of Sydenham chorea which affects pregnant women, in the first and second trimester of pregnancy and occurs mainly in women who had at least one episode of Sydenham chorea in childhood.

Usually, the disease resolves spontaneously in 3 to 6 months and rarely lasts longer than 1 year. In a small percentage of cases, a mild choric syndrome, without functional disability,  may appear after 10 years from the initial attack of Sydenham chorea. Disease recurrences are rare, about 20% of patients  may experience 2 to10 recurrences, usually within the first 2 years after the initial attack.

Sydenham Chorea Diagnosis

Sydenham chorea diagnosis may be difficult because, until now no specific test is available. Disease usually develops after 1 to 6 months  from a preceding streptococcal infection, but patient may not present a history of rheumatic fever and a preceding streptococcal infection cannot always be documented, due to the fact that infections can have a  subclinical evolution. In 25% of Sydenham chorea cases, serologic markers of streptococcal infection can not be highlighted.

In classical cases of rheumatic fever in which chorea is the main symptom may be highlighted cardiac or joint impairments and modified laboratory tests (increased ESR, increased C-reactive protein, increased ASO titer).

Sydenham Chorea Treatment

Due to the fact that Sydenham chorea is a self-limited disease, treatment should be administrated to particular cases with severe evolution.

Anticonvulsant medications (valproic acid and carbamazepine) have proven effective in reducing choreic movements. Other drugs such as dopamine blockers (haloperidol, pimozide and clozapine) are also useful in the treatment of rheumatic chorea, especially in older children. Tetrabenazine and reserpine, as depletion dopamine agents are useful in choreic movements control, but present adverse effects such as dizziness, akathisia and dyskinesia.

Corticosteroid therapy was also used for a long time to treat rheumatic chorea, but no studies have been done in order to confirm its effectiveness.

Immunological therapy (intravenous immunoglobulin and plasmapheresis) is useful in the treatment of Sydenham chorea, but presents important side effects and is very expensive.

Another important aspect of treatment is antibiotherapy against streptococcal infection. Penicillin is administrated, amoxicillin for children. If the patient is allergic to penicillin, erythromycin or second generation cephalosporins are recommended. Children with Sydenham chorea require prophylaxis against streptococcal infections until 18 years of age.


Breast Cancer Cells

Researchers in Australia have now found the mechanism by which breast tumors manage to metastasize without being attacked by the immune system. It seems that cancer cells block the production of interferon, and thus the immune response. Interferon is a protein that is released when the body comes into contact with bacteria, viruses, parasites, tumoral cells and so on. This protein serves as a trigger for the immune response to protect the body from foreign cells.

The study, published in Nature Medicine, found that cancer cells are able to inhibit IRF7 gene responsible for production of interferon . Once blocked the production of interferon, cancer cells can metastasize easily in bone marrow. To reach these conclusions, researchers have studied biopsies taken from mice with breast cancer. To check the potential of this discovery, researchers have thought at two methods. One of them was to administer interferon to mice, and the result was positive. A second attempt was to put the gene back into cells in place so that it can not be blocked by cancer cells. Although both trials were successful (cancer did not metastasize) researchers believe that  more tests are needed in order to create a new therapy against metastatic cancer.

Breast Cancer Cells

Breast Cancer Cells

Researchers felt the importance of interferon long time ago. Therefore,  interferon therapy is used in several diseases such as viral hepatitis, with antiviral drugs, autoimmune diseases (multiple sclerosis), etc.. Also, interferon therapy is used in several cancers, especially hematological cancers (leukemias, lymphomas). Melanomas (skin cancers) also benefit from treatment with interferon. Breast cancer derives from mammary tissue and is one of the most common cancers in women. It can affect men, but rarely, and when it occurs in men is associated with a much worse prognosis. Prognosis in women depends very much on the type of cancer and cancer stage. If found early, in the absence of metastases ( bone, lung, liver, brain), cancer can be cured. The most common symptom of breast cancer is the appearance of  a lump in the breast. The nodule is poorly defined, firm, adheres to the deep tissue and skin surface may appear orange peel. Moreover, another visible sign is the inverted nipple. General signs of cancer may also be present, consisting of weight loss without any aparent cause, anorexia, asthenia. The current treatment of breast cancer relies on surgery (mastectomy, lumpectomy, quadrantectomy), hormone blocking therapy (cancers that have estrogen receptors), chemotherapy, immunotherapy (monoclonal antibodies, transtuzumab, ) and radiotherapy.


New Real-Time Imaging Technique To Be Used In Cancer

Assistant Professor Chao Zhou says that there is a possible improvement to modern-day imaging technology used for the detection of malignant tumors. This new method combines two already available technologies: confocal microscopy and optical coherence tomography (also known as OCT).

“As many as 40 percent of breast cancer patients now have to undergo a second surgery, because part of the tumor is left behind during the first” said Chao Zhou, while also adding that combining the two methods will allow a better localization of the tumor and will give surgeons the possibility to entirely remove the tumor through the first surgery.

The main advantage of this new approach is that the tissue can now be examined without causing any damage. The current method of examining cancerous tissue is to section it, stain it and then examine it under a microscope. This method is currently known as histopathology. The new technique could also give information on embryonic forms of cancer.

Optical coherence tomography allows the 3D imaging of the tissue through the recognition and analysis of the light patterns created by the internal organs. The confocal microscopy technique creates very high-resolution images but is not able to penetrate the tissues as deep as the optical coherence tomography. The combination of the two, known as the optical coherence microscopy (OCM), is able to create in-depth high-resolution imaging.

Optical Coherence Microscopy

Optical Coherence Microscopy

Professor Zhou says that his goal is to provide a real-time imaging technique capable of providing images of the microstructures found in the tissues at resolutions that are close to the ones used in histopathology at the moment. Zhou is also a pioneer in the use of optical coherence tomography in detecting cancerous tissue.

According to Zhou, the current imaging techniques do not provide an instant result, whilst OCT is capable of providing real-time images. Using a combination of the two methods,  optical coherence tomography and optical coherence microscopy, Zhou is able to alternate the high and low resolutions. Through this method he has managed to identify groups of cancerous cells without damaging or removing the tissue.

Professor Zhou also added that he is currently using OCT and OCM to study the development of an embryo or an animal. The method allows studying the development without having to sacrifice the particular embryo or animal. Another use of OCT could be the imaging of the systolic and diastolic rhythm of an embryonic heart. This would allow real-time examination, thus allowing the imaging of the heart rhythm, otherwise impossible to image in a dead heart.


Avastin Found Effective Against Platinum Resistant Ovarian Cancer

According to the results of a study presented at the annual conference of the American Society of Clinical Oncology in Chicago, chemotherapy-bavacizumab dual therapy increases survival duration in patients with ovarian cancer.

Ovarian cancer is a type of malignancy often fatal as  it is usually diagnosed in its late stages. Worldwide, more than 230 000 women are suffering from ovarian cancer and about 70% of them die within 5 years after the diagnosis. Risk factors for ovarian cancer include late menopause and nuliparity. Family history of breast cancer, endometrial or colon cancer also increases the risk of developing ovarian cancer. Moreover, BRCA gene mutations are responsible for about 15% of  all ovarian cancers cases.

Ovarian cancer is aggressive by direct extension of the cancer cells. A particular feature of this cancer is peritoneal seeding, expansion of cancer cells in the peritoneum. Metastasis can occur by hematogenous way to liver or to the lungs. Sometimes it is diagnosed when complications occur such as ascites or intestinal obstruction. In terms of symptoms, ovarian cancer may be asymptomatic in its early stages. There are cases when women see the doctor for severe abdominal pain caused by torsion of the tumor mass. In some cases a palpable abdominal mass, hard, irregular and fixed is discovered by the clinician. Usually, symptoms are nonspecific and consist of nausea, bloating, dyspepsia, back pain, early satiety. During its evolution  flatulence, pelvic pain, anemia and cachexia may also occur.

Treatment varies depending on the type of cancer and disease stage. Generally, curative treatment consists of surgery (hysterectomy, bilateral adnexectomy and lymphadenectomy) combined with chemotherapy. Chemotherapy after surgery is performed to remove residual tumor tissue. There are also cases in which chemotherapy is performed before the surgical act.

Bevacizumab (Avastin) is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thus inhibiting angiogenesis. This drug is used in many types of cancers, such as breast cancer, kidney cancer, lung cancer, ovarian cancer, colorectal cancer and glioblastoma . Although it was initially approved for metastatic breast cancer, it was later revoked because it was found that does not improve survival rates.



Recently, after an international, randomized clinical phase 3 trial, it was found that bevacizumab in combination with standard chemotherapy increases survival rate in patients with ovarian cancer. The study included 361 patients with ovarian cancer. Those receiving standard therapy and bevacizumab had a median time of progression free survival of 6.7 months while those treated only with standard therapy had a median time of progression free survival of 3.4 months. Lead study author Eric Pujada-Lauraine, a professor at Universite de Paris Descartes, noted that for the first time researchers were able to increase the duration of survival in patients with platinum resistant ovarian cancer.